Novo Nordisk’s Three-Pronged Strategy Amid Pricing Headwinds

This week, the Danish pharmaceutical giant Novo Nordisk executed a multi-faceted strategic push across three distinct areas. The company launched a subscription model for its weight-loss drug Wegovy, released clinical data positioning it against a newly approved rival from Eli Lilly, and confirmed its upcoming dividend payment on April 8th. These moves unfold against one of the most challenging pricing environments in the firm’s history.

Structural Challenges and a Tariff Reprieve

Despite an active week, the broader operating landscape remains demanding. For the current year, Novo Nordisk forecasts an adjusted sales decline of five to 13 percent at constant exchange rates. This projection stems from a pricing agreement with the U.S. government under the Most-Favored-Nation clause and reduced Medicaid reimbursements for obesity medications.

On a positive note, the company has secured some relief on the tariff front. Firms that have negotiated price reductions with the White House, including Novo Nordisk, Eli Lilly, Pfizer, and AstraZeneca, will be exempt from new pharmaceutical tariffs for three years. Companies without such agreements face a 100 percent duty on patented medicines.

Subscription Model Aims to Lock In Patients

A key customer-focused initiative went live on March 31st. U.S. patients can now enroll in a Wegovy subscription plan via telehealth providers such as Ro, WeightWatchers, or LifeMD. Opting for an annual subscription lowers the cost for the injectable version to $249 per month, compared to $329 for a three-month plan. Annual savings can reach up to $600 for the tablet version and up to $1,200 for the pen.

The strategy has a clear dual purpose: to standardize pricing through digital channels without officially cutting the list price, and to foster long-term patient loyalty. In a therapeutic area where treatment adherence directly drives revenue, this subscriber approach is considered crucial.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Clinical Data Positions Wegovy Against New Rival

Novo Nordisk swiftly responded to regulatory news from its main competitor. Just one day after the FDA approved Eli Lilly’s new oral GLP-1 drug, Orforglipron (marketed as Foundayo), Novo presented study data favoring its own Wegovy tablet (25 mg). Based on an indirect, population-adjusted comparison from the ORION study, oral semaglutid achieved approximately three percentage points more weight reduction than the 36 mg dose of Orforglipron.

The company also highlighted a tolerability advantage. Its analysis suggested patients were 14 times more likely to discontinue Orforglipron treatment due to gastrointestinal side effects. In a separate patient survey (OPTIC), 84 percent of respondents preferred the clinical profile of the Wegovy tablet.

It is important to note that Novo’s calculations rely on previously published studies rather than fresh head-to-head trial data. The robustness of this indirect comparison will likely be scrutinized by competitors and independent analysts.

Upcoming Catalysts: CagriSema and Strategy Update

Looking ahead, the next significant catalyst for investors is the FDA’s decision on CagriSema, a combination therapy of cagrilintide and semaglutid for obesity treatment. Approval is anticipated around the turn of the year 2026/2027.

Before that, the Capital Markets Day scheduled for September 2026 is expected to be a major event. Novo Nordisk will likely use this platform to detail its mid-term strategic roadmap as it navigates persistent pricing pressures.